ERBB2 and breast cancer: The targeting efficiency showed that trastuzumab-loaded dendrimers bind specifically to SKBR3 breast cancer cells (HER2-positive) in a dose-dependent mode with a low binding affinity to MCF-7 cells (HER2-negative).